Brought to you by 
Targeted Genetics acquires Genovo for $69mm
21 Sep 2000
Executive Summary
Targeted Genetics (gene therapy products to treat acquired and inherited diseases) has acquired Genovo (private gene therapy company that focuses on early stage clinical development) with the issue of 6.63mm common shares. The transaction values Geneovo at $68.9mm, based on the stock's current market average.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Targeted Genetics acquires Genovo for $69mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice